Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
West Pharmaceutical's biologics exposure, Annex 1 projects and delivery-device growth support prospects despite near-term headwinds.
Zacks Investment Research9/18/2026Negative
WST
West Pharmaceutical Services IncNYSEHEALTHCAREMEDICAL INSTRUMENTS & SUPPLIES
Key Statistics
Market Cap
$26.07B
P/E Ratio
47.43
EPS
$7.81
Beta
1.14
52W High
$385.75
52W Low
$223.52
50-Day MA
$350.28
200-Day MA
$299.27
Dividend Yield
0.23%
Profit Margin
17.00%
Forward P/E
37.04
PEG Ratio
3.43
About West Pharmaceutical Services Inc
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.
Fundamentals
| Revenue (TTM) | $3.33B |
| Gross Profit (TTM) | $1.22B |
| EBITDA | $912.20M |
| Operating Margin | 22.50% |
| Return on Equity | 19.10% |
| Return on Assets | 11.40% |
| Revenue/Share (TTM) | $46.30 |
| Book Value | $42.47 |
| Price-to-Book | 6.71 |
| Price-to-Sales (TTM) | 7.84 |
| EV/Revenue | 6.57 |
| EV/EBITDA | 25.59 |
| Quarterly Earnings Growth (YoY) | 18.10% |
| Quarterly Revenue Growth (YoY) | 13.80% |
| Shares Outstanding | $70.38M |
| Float | $69.85M |
| % Insiders | 0.66% |
| % Institutions | 102.00% |
Historical Volatility
HV 10-Day
24.95%
HV 20-Day
23.02%
HV 30-Day
20.60%
HV 60-Day
25.35%
HV Rank
4.8%
Volatility is currently expanding
Analyst Ratings
Consensus ($407.56 target)
3
Strong Buy11
Buy2
HoldLatest News
West Pharmaceutical Services, Inc. (WST) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
West Pharmaceutical Services, Inc. (WST) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha9/14/2026Neutral
West Pharmaceutical Services, Inc. (WST) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
West Pharmaceutical Services, Inc. (WST) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Seeking Alpha9/10/2026Neutral
West to Participate in Upcoming Investor Conferences
EXTON, Pa., Aug. 26, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the following upcoming investor conferences: Wells Fargo Annual Healthcare Conference on Thursday, September 10, 2026 at 8:45 a.m. EDT in Everett, MA Morgan Stanley Annual Global Healthcare Conference on Monday, September 14, 2026 at 8:30 a.m.
PRNewsWire8/26/2026Neutral
WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?
West Pharmaceutical Services has surged 38.1% since March-end as HVP demand, GLP-1 growth and productivity gains fuel the rally.
Zacks Investment Research8/14/2026Positive
West Pharmaceutical (WST) Upgraded to Buy: Here's Why
West Pharmaceutical (WST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks Investment Research8/14/2026Positive
Should Investors Buy WST as HVP Growth Meets a Premium Valuation?
WST's faster HVP growth, wider margins and stronger earnings outlook support the bull case, but its premium valuation leaves less room for error.
Zacks Investment Research8/13/2026Positive
WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story
West Pharmaceutical's Q2 beat, faster HVP growth and wider margins drove a higher 2026 outlook, strengthening its earnings case.
Zacks Investment Research8/13/2026Positive
WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook
WST's HVP growth, wider margins and raised 2026 outlook support its recent rally, but a premium valuation raises the bar for further gains.
Zacks Investment Research8/13/2026Positive
West Pharmaceutical Delivers Another Beat - But The Real Story Is The Mix Shift
West Pharmaceutical Services delivered a strong 2Q26, beating on both revenue ($872.3M, +13.8% YoY) and EPS ($2.37, +$0.29 vs. consensus). WST raised full-year guidance to $3.345–$3.380B in sales and $8.85–$9.05 in EPS, reflecting confidence in sustained double-digit organic growth and margin expansion. High-Value Product components and biologics drove mix shift, with HVP now 49% of revenue and biologics up 29% organically, supporting durable margin gains.
Seeking Alpha7/24/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on WST and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/26/2026